Skip to main content

Veterinary deworming agent-induced toxic optic neuropathy: a case report



Veterinary antiparasitic drugs are widely used in countries and regions in which parasitic diseases are endemic, which leads to the risk of accidental ingestion and poisoning in humans. 

Case presentation

A 40-year-old male patient with a history of cirrhosis sought medical attention on November 25, 2021, due to progressive vision loss. He had previously taken triclabendazole and bithionol and was diagnosed with toxic optic neuropathy on examination. Steroid, neurotonic, and high-pressure oxygen therapy were ineffective.


Triclabendazole and bithionol have potential risk of optic neurotoxicity and should be considered for enhanced supervision and warning labels.

Peer Review reports


Endemic parasitic diseases present a major public health problem, which still affect developing countries. Even though some old antiparasitic drugs such as triclabendazole, bithionol, and niclofolan are no longer, or rarely, used in humans, a many of these drugs are used to treat parasitic diseases in livestock. Veterinary antiparasitic drugs are widely available in countries and regions with endemic parasitic diseases and, with the development of e-commerce, these drugs are easily purchased on the Internet. There have been many reports of accidental ingestion of antiparasitic drugs in humans, resulting in poisoning. This includes optic neurotoxicity caused by closantel and niclofolan [1,2,3], however there have been no reports of optic neurotoxicity caused by triclabendazole and bithionol.

Case presentation

A 40-year-old male patient sought medical attention at our hospital on November 25, 2021, due to progressive vision loss. According to his medical history, the patient suspected that he had parasitic worms and took the veterinary antiparasitic drug triclabendazole 0.7 g and bithionol 1.5 g, which he had purchased online, around 20 days ago. After taking the drug, he drank 500 ml of beer. After 2 days, he developed mild blurred vision in both eyes. After 1 week, he felt that the bilateral blurred vision had worsened. After 2 weeks, he experienced bilateral visual impairment accompanied by micturition and bowel movement difficulties and sought medical attention at a local hospital. No apparent abnormalities were observed in cranial and bilateral orbital MRI with contrast. Visual acuity did not improve after steroid and neurotonic treatments(dexamethasone 10 mg iv qd, mecobalamin 0.5 mg tid po), thus he sought medical attention at our hospital. The patient had a multi-year history of hepatitis B, cirrhosis, and gastric fundal varices. In October 2020, he was hospitalized for treatment due to liver failure and was on long-term entecavir, glutathione, polyene phosphatidyl choline, and ursodiol treatment. His hepatic function was stable and he was not taking other drugs. On admission, the patient was conscious and had bilateral visual impairment accompanied by micturition and bowel movement difficulties. Physical examination showed that light perception was absent in both eyes. Intraocular pressure was 12.0 mmHg and 13.7 mmHg in the right and left eyes, respectively. Bilateral pupil diameter was 4.5 mm, light reflex was absent, the optic disc boundary was clear, the fundus was pale-red in color, the C/D was around 0.3–0.4, and the retina was flat. There was no fundus bleeding or exudation and the fovea was reflective. Macular OCT showed bilateral macular retinal thinning, and disappearance of the outer retinal reflex (Fig. 1). Optic nerve OCT examination showed that RNFL thickness on the temporal side of the right eye was slightly thinner, as well as the nasal side of the left eye. However, due to the patient’s poor visual acuity and poor fixation during OCT examination, the above data did not pass baseline verification. Bilateral ocular FVEP showed a delay and decrease in amplitude of the P wave peak (Fig. 2). Fundus color photography showed both optic discs appeared pale (Fig. 3). The neurotonics citicoline (0.1 g bid po) and idebenone (30 mg tid po) were given and high-pressure oxygen therapy was administered. After 1 week of treatment, the patient’s bilateral visual acuity did not improve, and he was discharged. The patient’s visual acuity still had not improved after half a year of follow-up.

Fig. 1
figure 1

OCT inspection conducted on November 26th, 2021, about 3 weeks after taking triclabendazole and bithionol. OCT showed bilateral macular retinal thinning(OD:64 μm; OS:67 μm), and disappearance of the outer retinal reflex

Fig. 2
figure 2

FVEP conducted on November 26th, 2021, about 3 weeks after taking triclabendazole and bithionol. FVEP showed a delay and decrease in amplitude of the P wave peak

Fig. 3
figure 3

Fundus color photography conducted on November 26th, 2021, about 3 weeks after taking triclabendazole and bithionol. Fundus color photography showed both optic discs appeared pale

Discussion and conclusion

For treating fascioliasis and paragonimiasis in humans, the WHO recommends a dose of 10 mg/kg oral triclabendazole and the FDA recommends a total dose of 20 mg/kg, taken in two doses [4]. Adverse reactions to triclabendazole mainly include abdominal pain, biliary colic, transaminase elevation, and urticaria [4]. Before triclabendazole, bithionol was used as the first line antiparasitic drug. However, bithionol was discontinued due to its long treatment course, poor adherence, many side effects, and unclear therapeutic effects [5]. According to previous reports, the oral dose of bithionol is 25–50 mg/(kg·d) and 10–15 doses are taken. The incidence of side effects with bithionol is 41.2% and include mainly abdominal pain, diarrhea, and rashes [6]. Serious adverse reactions to bithionol have not been reported. One study reported improvements in visual acuity and visual field after bithionol treatment in patients with acute phases of cerebral paragonimiasis [7], indicating that the drug does not cause significant optic nerve toxicity in patients with normal hepatic and renal function. The patient in the current study took doses of oral triclabendazole and bithionol for humans with normal hepatic and renal function (11.9 mg/kg and 25.4 mg/kg, respectively), but developed progressive and irreversible vision loss. Since retinal hemorrhage, exudation, and optic disc edema, were not seen upon fundoscopy and optic nerve changes were not found MRI of the cranium and orbital, drug-induced toxic optic neuropathy was considered. Even though serious adverse reactions to triclabendazole and bithionol have not been reported clinically thus far [4, 8, 9], there have been no studies of the use of these drugs in patients with hepatic and renal insufficiency [5]. Since triclabendazole and bithionol are metabolized by the liver [10], the synergistic effects of underlying cirrhosis and alcohol use may have increased the toxicity of these two drugs. In addition, drug-drug interactions between triclabendazole and bithionol, as well as between antiparasitic drugs and anti-hepatitis B and hepatoprotective drugs are unclear. Further study regarding adverse interactions between these drugs is required to determine whether toxicity due to drug interactions. Steroids, neurotonic drugs, and early renal replacement treatment have been reported to be effective in treating closantel-induced optic neurotoxicity [2, 11,12,13]; however, vision loss did not improve in our patient after steroid and neurotonic treatment. The half-lives of triclabendazole and its active metabolites, sulfoxide, and sulfone, are 8, 14, and 11 h, respectively [10]. The concentration of bithionol in blood is significantly lower than in bile in which it reaches peak concentration 2 h after administration [14]. CRRT was not performed in our patient as more than 20 days had passed when he sought medical attention at our hospital.

In summary, this case study indicates that there is a potential risk for optic neurotoxicity with the use of triclabendazole and bithionol. Patients with inadequate liver function cannot use these drugs without the approval of a doctor, and patients taking these drugs should be closely monitored for possible optic neurotoxicity These drugs should not be allowed to be sold on the internet.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.



Magnetic resonance imaging


Optical Coherence Tomography


Retinal nerve fiber layer


Flash visual evoked potential


World Health Organization


Food and Drug Administration


Continuous renal replacement therapy


  1. Ghods S, Khalili Pour E, Riazi-Esfahani H, Faghihi H, Inanloo B. Closantel retinal toxicity: case report and literature review. Case Rep Ophthalmol Med. 2021;2021:1–4.

    Google Scholar 

  2. Khalili MR, Zareei A. Case report: restored vision after ocular Closantel intoxication and blindness. BMC Ophthalmol. 2021;21(1):158.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hong ST, Lee SH, Ahn HS, Yun CK. A case of niclofolan (Bilevon(R)) intoxication. Kisaengchunghak Chapchi. 1982;20(1):49–52.

    PubMed  Google Scholar 

  4. Marcos L, Maco V, Terashima A. Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures. Expert Rev Anti-Infe. 2021;19(7):817–23.

    Article  CAS  Google Scholar 

  5. Gandhi P, Schmitt EK, Chen C, Samantray S, Venishetty VK, Hughes D. Triclabendazole in the treatment of human fascioliasis: a review. T Roy Soc Trop Med H. 2019;113(12):797–804.

    Article  CAS  Google Scholar 

  6. Kim JS. Treatment of Paragonimus westermani infections with bithionol. Am J Trop Med Hyg. 1970;19(6):940.

    Article  CAS  PubMed  Google Scholar 

  7. Oh SJ. Bithionol treatment in cerebral paragonimiasis. Am J Trop Med Hyg. 1967;16(5):585.

    Article  CAS  PubMed  Google Scholar 

  8. Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P. Successful treatment of acute fascioliasis with bithionol. Hepatology. 1991;14(6):1066–9.

    Article  CAS  PubMed  Google Scholar 

  9. Farag HF, Salem A, El-Hifni SA, Kandil M. Bithionol (Bitin) treatment in established fascioliasis in Egyptians. J Trop Med Hyg. 1988;91(5):240–4.

    CAS  PubMed  Google Scholar 

  10. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-1082.

    Article  CAS  PubMed  Google Scholar 

  11. Cheraghmakani H, Jafari R, Karimpour-Razkenari E, Ghazaeian M. Reversible blindness after erroneous prescription of closantel: a case report. Clin Case Rep. 2021;9(12):e5157.

    Article  Google Scholar 

  12. Kumar K, Mishra C, Anjanamurthy R, Kannan NB, Ramasamy K. Reversible blindness in a patient with closantel toxicity. Indian J Ophthalmol. 2019;67(10):1768–71.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Koziolek MJ, Patschan D, Desel H, Wallbach M, Callizo J. Closantel poisoning treated with plasma exchange. JAMA OPHTHALMOL. 2015;133(6):718–20.

    Article  PubMed  Google Scholar 

  14. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388-1395.

    Article  CAS  PubMed  Google Scholar 

Download references


Not applicable.


No funding.

Author information

Authors and Affiliations



LQ and KW were the major contributors to the drafting of the manuscript. YO reviewed the article. LP examined the patient and analyzed data. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Long Pang.

Ethics declarations

Ethics approval and consent to participate

This study complied with the tenets of the Declaration of Helsinki. The ethics committee of Guangdong Provincial Hospital of Chinese Medicine hospital approved the study.

Consent for publication

Written consent for the publication of identifying clinical/personal information and images was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qin, L., Wang, K., Ou, Y. et al. Veterinary deworming agent-induced toxic optic neuropathy: a case report. BMC Ophthalmol 23, 357 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: